New Drug Approvals Archive
New Drug Approvals: April 2006
| April 6 | Daytrana (methylphenidate) Transdermal System - formerly MTS Date of Approval: April 6, 2006 Company: Shire Pharmaceuticals Group plc / Noven Pharmaceuticals, Inc. Treatment for Attention Deficit Hyperactivity Disorder (ADHD) Daytrana is a once daily transdermal patch formulation of methylphenidate indicated for the treatment of attention deficit hyperactivity disorder (ADHD). Daytrana Approved - Shire plc - Treatment for Attention Deficit Hyperactivity Disorder |
| April 13 | NeoProfen (ibuprofen lysine) Injection Date of Approval: April 13, 2006 Company: Farmacon-IL, LLC Treatment for Patent Ductus Arteriosus NeoProfen is an intravenous formulation of ibuprofen lysine indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants, who are no more than 32 weeks gestational age when usual medical management is ineffective. NeoProfen Approved - Farmacon-IL, LLC - Treatment for Patent Ductus Arteriosus |
| April 13 | Vivitrol (naltrexone) Long-Acting Injection - formerly Vivitrex Company: Alkermes, Inc. Treatment for Alcohol Dependence Vivitrol Approved - Alkermes Inc. and Cephalon Inc - Treatment for Alcohol Dependence |
| April 28 | Myozyme (alglucosidase alfa) Date of Approval: April 28, 2006 Company: Genzyme Corp. Treatment for Pompe disease Myozyme is a recombinant formulation of the human enzyme acid alpha-glucosidase (GAA) indicated for use in patients with Pompe disease (GAA deficiency), a debilitating and often fatal muscle disorder. Myozyme Approved - Genzyme Corp. - Treatment for Pompe Disease |
New Drug Approvals Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Oct | Dec




